Ali-Ahmad HM et al. Pertuzumab plus trastuzumab (P+T) in patients (pts) with uterine cancer (UC) with ERBB2 or ERBB3 amplification, overexpression or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. ASCO 2021;Abstract 5508.
Buza N. HER2 testing and reporting in endometrial serous carcinoma: Practical recommendations for HER2 immunohistochemistry and fluorescent in situ hybridization: Proceedings of the ISGyP companion society session at the 2020 USCAP annual meeting. Int J Gynecol Pathol 2021;40(1):17-23. Abstract
Buza N et al. Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: A multi-institutional interobserver agreement study. Mod Path 2021;34(6):1194-202. Abstract
Hasegawa K et al. Efficacy and safety of trastuzumab deruxtecan in HER2-expressing uterine carcinosarcoma (STATICE trial, NCCH1615): A multicenter, phase II clinical trial. ESMO 2021;Abstract 813P.
Ikeda S et al. Primary results from JUPITER, a phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with HER2-amplified solid tumors. ASCO 2022;Abstract 3131.
Itkin B et al. Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis. PLoS One 2021;30:16(9). Abstract
Lin MY et al. Prognostic significance of FIGO 2018 staging of loco-regionally advanced cervical cancer (LRACC) with the use of MRI and PET and implications for treatment selection. Gynecol Oncol 2022;169:91-7. Abstract
Meric-Bernstam F et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 2023;[Online ahead of print]. Abstract
Meric-Bernstam F et al. Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim result. ASCO 2023;Abstract LBA3000.
Meric-Bernstam F et al. Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study. ESMO 2023;Abstract LBA34.
Nishikawa T et al. Trastuzumab deruxtecan for human epidermal growth factor receptor 2-expressing advanced or recurrent uterine carcinosarcoma (NCCH1615): The STATICE trial. J Clin Oncol 2023;41(15):2789-99. Abstract
Selenica P et al. Massively parallel sequencing analysis of 68 gastric-type cervical adenocarcinomas reveals mutations in cell cycle-related genes and potentially targetable mutations. Mod Pathol 2021;34(6):1213-25. Abstract
Shen S et al. Clinicopathologic and molecular features associated with response to anti-HER2 therapy in endometrial cancer. ASCO 2022;Abstract 5584.
Tarantino P et al. Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates. JAMA Oncol 2021;7:1873. Abstract